| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/25/2009 | EP2027144A1 Macrocyclic compounds as antiviral agents |
| 02/25/2009 | EP2027139A1 Crystalline a and b forms of a maleate salt of 5-amino-3- (2 ', 3 '-di-o-acetyl-beta-d-ribofuranosyl) -3h-thiazolo [4, 5-d]pyrimidin-2-one |
| 02/25/2009 | EP2027125A1 Pentacyclic indole derivatives as antiviral agents |
| 02/25/2009 | EP2026841A2 Conjugation process for pnag and a carrier protein |
| 02/25/2009 | EP2026825A2 Furanone-initiated polymers |
| 02/25/2009 | EP2026774A1 Improved method of treatment of bacterial infections |
| 02/25/2009 | EP1506188B1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/25/2009 | EP1240326B1 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify this receptor |
| 02/25/2009 | EP1143965B1 Carbocyclic potassium channel inhibitors |
| 02/25/2009 | EP1015445B1 Antimicrobial quinolones, their compositions and uses |
| 02/25/2009 | CN101374849A Quinoline-4-ketones derivates as ABC transport protein regulation/control agent |
| 02/25/2009 | CN101374845A Novel compounds and use thereof |
| 02/25/2009 | CN101374844A Pyrrolopyridazinone compound |
| 02/25/2009 | CN101374831A Tetrahydropyrane antibiotics |
| 02/25/2009 | CN101374801A Histone deacetylase inhibitors for enhancing activity of antifungal agents |
| 02/25/2009 | CN101374547A Vaccine for in ovo inoculation |
| 02/25/2009 | CN101374532A Use of gallium to treat biofilm-associated infectons |
| 02/25/2009 | CN101374531A Use of hyaluronic acid as a carrier molecule for different classes of therapeutic active agents |
| 02/25/2009 | CN101374509A Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| 02/25/2009 | CN101374502A Medicament for topical use |
| 02/25/2009 | CN101374501A Composition and method of use thereof |
| 02/25/2009 | CN101372490A Penem derivative containing sulfhydryl nitrogen heterocyclic ring and vinyl nitrogen heterocyclic ring |
| 02/25/2009 | CN101372489A Carbapenem derivative containing sulfhydryl pyrrolidine formamide benzyl |
| 02/25/2009 | CN101372488A Novel carbapenem compound |
| 02/25/2009 | CN101372486A Preparation of abafungin and analogues thereof |
| 02/25/2009 | CN101371920A Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 02/25/2009 | CN101371911A Chinese medicinal composition for treating flat wart |
| 02/25/2009 | CN101371889A A set of medicament prescription for treating skin tinea and preparation method thereof |
| 02/25/2009 | CN101371881A Chinese medicine soft capsule formulation for treating hepatosis and preparation technique thereof |
| 02/25/2009 | CN101371871A Echinacea purpurea five-component oral spray |
| 02/25/2009 | CN101371861A High-efficient antiviral medicament composition in chickweed as well as preparation method and use thereof |
| 02/25/2009 | CN101371841A Crystallization type Entecavir formulation as well as preparation method and use thereof |
| 02/25/2009 | CN101371832A Medical use of triacetyl andrographolide as proinflammatory cytokine inhibitor |
| 02/25/2009 | CN100463917C Reductive alkylation of glycopeptide antibiotics |
| 02/25/2009 | CN100463694C Virus coat protein/receptor chimeras and methods of use |
| 02/25/2009 | CN100463679C Clarithromycin soft capsule and its preparation |
| 02/25/2009 | CN100463673C Compound medicine release controlling film of chitosan, sodium alginate and gelatin and its preparing process |
| 02/25/2009 | CN100463670C Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same |
| 02/24/2009 | US7495114 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/24/2009 | US7495088 Nuclease resistant nucleotide capable of hybridizing with complementary RNA in a manner which inhibits function of the RNA |
| 02/24/2009 | US7495027 drugs that inhibit biosynthesis of bacterial cell walls, such as (5Z)-5-[(3',5'-dichloro-1,1'-biphenyl-3-yl)methylene]-3-(3,5-dichlorophenyl)-4-hydroxyfuran-2(5H)-one, used for treatment of bacterial infections, and as parasiticides |
| 02/24/2009 | US7495018 An enzyme inhibitor of p38 MAP kinase, an antagonist of tumor necrosis factors or adenosine receptor, a thiazole with the 5-pyridyl group derivatives |
| 02/24/2009 | US7495014 Gyrase inhibitors and uses thereof |
| 02/24/2009 | US7495011 Anti-coronavirus drug |
| 02/24/2009 | US7494991 For microbial infections specially Gram-positive bacterial infection; atherosclerosis-associated disease |
| 02/24/2009 | US7494988 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| 02/24/2009 | US7494984 Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| 02/24/2009 | US7494975 A polyanion selected from a heparin, a dextran, a pentosan, resobene, curdian sulfate, or 2-naphthalene sulfonate polymer and a CD4 polypeptide with a beta-hairpin confirmation; blocking HIV interaction with coreceptors |
| 02/24/2009 | US7494824 Interactive system for presenting and eliminating substances |
| 02/24/2009 | US7494808 Methods and interferon deficient substrates for the propagation of viruses |
| 02/24/2009 | US7494785 Recombinant subunit vaccine |
| 02/24/2009 | US7494768 Mutational profiles in HIV-1 protease and reverse transcriptase correlated with phenotypic drug resistance |
| 02/24/2009 | US7494767 Assay for TSG101 as inhibitors of HIV production |
| 02/24/2009 | US7494657 Inhibitor of hepatitis B and HIV activity |
| 02/24/2009 | US7494653 Inoculating a patient with an effective amount of PcrV antigen; monoclonal antibodies specific for the PcrV antigen |
| 02/24/2009 | CA2426221C New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds |
| 02/24/2009 | CA2370372C Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
| 02/24/2009 | CA2362601C Deep penetrating antimicrobial compositions |
| 02/24/2009 | CA2334568C Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems |
| 02/24/2009 | CA2316972C Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
| 02/24/2009 | CA2312943C Constitutive expression of non-infectious hiv-like particles |
| 02/24/2009 | CA2224438C Vinyl-pyrrolidinone cephalosporins with basic substituents |
| 02/24/2009 | CA2194236C Helicobacter proteins and vaccines |
| 02/24/2009 | CA2152949C Vaccine preparations |
| 02/19/2009 | WO2009023487A1 Tetracyclic compounds for the treatment of hepatitis c |
| 02/19/2009 | WO2009023332A2 Device and method for purifying virally infected blood |
| 02/19/2009 | WO2009023196A1 Modulation of immune responses by administration of roxithromycin or its derivative |
| 02/19/2009 | WO2009023179A2 Nitrogen containing bicyclic chemical entities for treating viral infections |
| 02/19/2009 | WO2009023160A2 Novel inhibitors of bacterial sortase enzymes and methods of using the same |
| 02/19/2009 | WO2009022185A2 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
| 02/19/2009 | WO2009022100A1 Composition comprising particles of metal compound |
| 02/19/2009 | WO2009021971A2 Novel targets and compounds for therapeutic intervention of hiv infection |
| 02/19/2009 | WO2009021696A1 Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 02/19/2009 | WO2009021488A1 Antioxidantcomplex based on grape vital (based on citrus seed and/or grape seed and/or flavonoid) |
| 02/19/2009 | WO2009021404A1 (1s, 2s, 3s, 4r)-3-[(1s)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof |
| 02/19/2009 | WO2008155520A3 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain |
| 02/19/2009 | WO2008154246A8 Hiv integrase inhibitors |
| 02/19/2009 | WO2008148057A3 Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| 02/19/2009 | WO2008142517A3 Synthetic peptide having anti-inflammatory and anti-microbic properties |
| 02/19/2009 | WO2008131746A3 Means for preventative anti-infective treatment of a patient |
| 02/19/2009 | WO2008118013A3 Targeted intracellular delivery of antiviral agents |
| 02/19/2009 | WO2008086529A3 Compositions and methods for targeted inactivation of hiv cell surface receptors |
| 02/19/2009 | WO2008008854A8 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| 02/19/2009 | US20090048461 Regulators of Bacterial Signalling Pathways |
| 02/19/2009 | US20090048435 Oligonucleotide modulation of cell adhesion |
| 02/19/2009 | US20090048350 Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method |
| 02/19/2009 | US20090048333 Zearalenone Macrolide Derivatives and Uses of the Same |
| 02/19/2009 | US20090048310 Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus |
| 02/19/2009 | US20090048307 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of |
| 02/19/2009 | US20090048293 Methods for treating bacillus infection |
| 02/19/2009 | US20090048291 Novel Piperidine-4-Acetic Acid Derivatives and Their Use |
| 02/19/2009 | US20090048285 Pyrrolopyridines Useful in the Treatment of Inflammation |
| 02/19/2009 | US20090048249 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| 02/19/2009 | US20090048247 Condensed isoxaline derivatives as inhibitors of phosphodiesterase type - iv |
| 02/19/2009 | US20090048242 (1,10b-dihydro-2-(aminoalkyl-phenyl)-5h-pyrazolo[1,5 c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors |
| 02/19/2009 | US20090048240 1,3-oxazinan-2-one compounds; antibiotic resistance |
| 02/19/2009 | US20090048239 Therapeutic compounds |
| 02/19/2009 | US20090048226 Inhibitors of caspases |
| 02/19/2009 | US20090048222 Triaza Compound Immunoregulatory Agents |
| 02/19/2009 | US20090048209 Compositions comprising dc-sign blockers and methods of using dc-sign blockers for preventing or treating diseases of a mammal, including viral infections |